Emmanuelle Waubant
Waubant, Emmanuelle L.
Waubant, Emmanuelle.
VIAF ID: 311802669 (Personal)
Permalink: http://viaf.org/viaf/311802669
Preferred Forms
- 100 0 _ ‡a Emmanuelle Waubant
- 100 1 _ ‡a Waubant, Emmanuelle L
-
-
-
- 100 1 _ ‡a Waubant, Emmanuelle L.
-
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Demyelinating disorders of the central nervous system in childhood | |
Dzieci "inerferonowe" | |
Editors' Welcome: Pregnancy and progressive multifocal leukoencephalopathy | |
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica | |
Examining the contributions of environmental quality to pediatric multiple sclerosis. | |
Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures | |
The gut microbiome in human neurological disease: A review | |
Gut microbiota composition and relapse risk in pediatric MS: A pilot study | |
Heterogeneity in association of remote herpesvirus infections and pediatric MS | |
How should we proceed with disease-modifying treatments for multiple sclerosis? | |
Impact of an electronic monitoring device and behavioral feedback on adherence to multiple sclerosis therapies in youth: results of a randomized trial. | |
Improving outcomes in multiple sclerosis through early diagnosis and effective management | |
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome | |
International Pediatric MS Study Group Global Members Symposium report | |
Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis 1 / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking | |
Longitudinal associations between brain structural changes and fatigue in early MS. | |
Longitudinally extensive optic neuritis in pediatric patients | |
MS and related disorders: groundbreaking news | |
MS and the B cell controversy | |
Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls | |
Multiple sclerosis susceptibility genes: associations with relapse severity and recovery | |
Multiple sclerosis tremor and the Stewart-Holmes manoeuvre | |
Neuroprotection in multiple sclerosis: a therapeutic approach | |
Neuropsychological correlates of multiple sclerosis across the lifespan | |
NMDA receptor encephalitis mimicking seronegative neuromyelitis optica | |
The onset location of multiple sclerosis predicts the location of subsequent relapses | |
Ovarian aging is associated with gray matter volume and disability in women with MS. | |
Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices | |
Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis | |
Precision medicine in chronic disease management: The multiple sclerosis BioScreen | |
Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls. | |
Proof of concept studies for tissue-protective agents in multiple sclerosis | |
Protective environmental factors for neuromyelitis optica | |
Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures | |
Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study | |
Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation-Reply | |
Recommendations for observational studies of comorbidity in multiple sclerosis | |
Refining the Nosology of Antigen-Specific Diseases Within the Spectrum of Neuromyelitis Optica | |
Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS | |
Retinal axonal loss in very early stages of multiple sclerosis | |
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. | |
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial | |
Rozpoznawanie stwardnienia rozsianego : aktualizacja kryteriów McDonalda w 2017 roku = Diagnosis of multiple sclerosis : 2017 revisions of the McDonald criteria | |
Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis | |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS. | |
Sex differences and subclinical retinal injury in pediatric-onset MS. | |
Spinal cord gray matter atrophy correlates with multiple sclerosis disability | |
Switching multiple sclerosis patients with breakthrough disease to second-line therapy | |
T cell gelatinases mediate basement membrane transmigration in vitro. | |
Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. | |
Treatment of multiple sclerosis in children and adolescents | |
Unilateral thalamic deep brain stimulation for disabling kinetic tremor in multiple sclerosis. | |
Update on biomarkers in neuromyelitis optica | |
The US Network of Pediatric Multiple Sclerosis Centers: Development, Progress, and Next Steps | |
Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder | |
Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US | |
Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype? | |
Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection | |
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis | |
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis | |
Younger children with MS have a distinct CSF inflammatory profile at disease onset |